<DOC>
	<DOCNO>NCT00536081</DOCNO>
	<brief_summary>The purpose study prevent chemotherapy-related febrile neutropenia , prophylaxis antibiotic granulocyte colony-stimulating factor ( G-CSF ) proven efficacious [ 1-3 ] . G-CSF side effect , expensive . In 2006 , update G-CSF guideline conclude primary G-CSF prophylaxis clinical benefit offer patient 20 % risk febrile neutropenia . Based many positive negative trial , one consider use taxanes standard care adjuvant set node-positive breast cancer . Taxanes ( without anthracyclines ) increase risk febrile neutropenia . The updated guideline change daily clinical practice significant impact investigator health care resource . There high risk febrile neutropenia first chemotherapy cycle compare subsequent cycle small cell lung cancer patient . Also advance breast cancer majority first observe episode febrile neutropenia occur initial chemotherapy cycle Irrespective tumour type chemotherapy regimen , risk febrile neutropenia high first two cycle chemotherapy . Thereafter , risk rapidly decline , benefit G-CSF largely seem disappear . So , order improve cost-effective administration primary G-CSF prophylaxis , justified ass whether G-CSF prophylaxis limit first two chemotherapy cycle compare current practice continuous G-CSF prophylaxis .</brief_summary>
	<brief_title>Various G-CSF Regimens Prevent Infection During Chemotherapy</brief_title>
	<detailed_description>1 . Febrile neutropenia Febrile neutropenia serious side effect cancer treatment . Febrile neutropenia predisposes serious sometimes life-threatening infection . Given seriousness , majority febrile neutropenia patient admit hospital treatment intravenous antibiotic . Thus , chemotherapy-induced febrile neutropenia result death , increase hospitalisation intravenous antibiotic use . In addition , lead significant chemotherapy dose modification , may theoretically concern treatment curative intent . Clearly , prevention chemotherapy-induced febrile neutropenia medical priority . 2 Prophylaxis febrile neutropenia To prevent chemotherapy-related febrile neutropenia , prophylaxis antibiotic granulocyte colony-stimulating factor ( G-CSF ) proven efficacious [ 1-3 ] . The use G-CSF show shorten duration neutropenia , result reduction incidence febrile neutropenia , hospitalisation use intravenous therapeutic antibiotic approximately 50 % . .Antibiotics may , however , lead emergence microbial resistance . G-CSF side effect , expensive . Previous guideline recommend primary G-CSF prophylaxis prevent febrile neutropenia , patient substantial risk febrile neutropenia ( 40 % ) . In 2006 , update G-CSF guideline conclude primary G-CSF prophylaxis clinical benefit offer patient 20 % risk febrile neutropenia . Most recent EORTC-reviewed evidence indicate primary secondary G-CSF prophylaxis significant impact survival , despite fact G-CSF prophylaxis enable maintain chemotherapy dose dose intensity . In GEICAM 9805 study , primary G-CSF support lead improve median dose intensity cumulative dose compare secondary G-CSF prophylaxis , although percentage patient complete six cycle therapy increase significantly . 3 . Developments adjuvant treatment breast cancer After introduction taxanes treatment advance breast cancer late ninety , agent also introduce ( neo ) adjuvant set . Many adjuvant trial positive outcome recently report . Based available data many positive negative trial , one consider use taxanes standard care adjuvant set node-positive breast cancer , although preferred schedule , concurrent sequential , without dose-densification , need clarified ongoing trial . Martin et al . report result randomize adjuvant trial compare TAC FAC high-risk N0 breast cancer patient , GEICAM 9805 trial . Comparisons report toxicity quality life . Only secondary G-CSF prophylaxis allow even mandatory episode febrile neutropenia . After protocol amendment , patient TAC arm receive primary G-CSF prophylaxis . So , addition upfront plan comparison TAC versus FAC , unplanned comparison TAC-pre versus TAC-post amendment report . This comparison interesting , knowledge first comparison primary versus secondary G-CSF prophylaxis ever report . The use primary G-CSF prophylaxis significantly reduce incidence febrile neutropenia associate TAC chemotherapy . The percentage patient febrile neutropenia one cycle 24.6 % 6.5 % TAC-pre TAC-post , respectively . Of note , TAC-pre group 71.1 % patient receive secondary G-CSF prophylaxis average 4 cycle treatment . In FAC group , 2.3 % patient febrile neutropenia per protocol definition . So , combine use anthracyclines taxanes come considerable increase risk febrile neutropenia . Perez conclude editorial New England Journal Medicine basis available data , one consider TAC ( docetaxel , adriamycin , cyclophosphamide ) standard care , dose-dense regimen doxorubicin cyclophosphamide follow paclitaxel , patient node-positive breast cancer . With regimen , prophylactic growth-factor support necessary ameliorate myelosuppression febrile neutropenia . 4 . Consequences health care cost We recently report , even patient considerable risk febrile neutropenia , primary G-CSF prophylaxis come considerable extra cost Netherlands : average € 5,123 per patient baseline risk febrile neutropenia 32 % . The updated guideline change daily clinical practice significant impact health care resource . In Netherlands several thousand patient many tumour type require primary G-CSF prophylaxis , lead cost increase least € 10-20 million per year . 5 . Rationale present study It demonstrate high risk febrile neutropenia first chemotherapy cycle compare subsequent cycle small cell lung cancer patient . Also advance breast cancer majority first observe episode febrile neutropenia occur initial chemotherapy cycle . With primary G-CSF prophylaxis absolute neutrophil count nadir less deep shorter duration later cycle compare first cycle . This may suggest may prim effect G-CSF subsequent cycle , emphasize administration G-CSF early course treatment might important . So , irrespective tumour type chemotherapy regimen , risk febrile neutropenia high first two cycle chemotherapy . Thereafter , risk rapidly decline , benefit G-CSF largely seem disappear . So , order improve cost-effective administration primary G-CSF prophylaxis , justified ass whether G-CSF prophylaxis limit first two chemotherapy cycle compare current practice continuous G-CSF prophylaxis .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>Breast cancer patient ≥18 year . Indication 3weekly chemotherapy . Considered fit enough receive chemotherapy , adequate renal hepatic function . Planned chemotherapy regime adjuvant , neoadjuvant , advanced setting increase risk febrile neutropenia , i.e . : Regimes &gt; 20 % risk febrile neutropenia : e.g . TAC ( docetaxel , adriamycin , cyclophosphamide ) AT ( adriamycin , docetaxel ) Regimes 1020 % risk febrile neutropenia ( e.g . AC , doxorubicin vinorelbine , docetaxel monotherapy ) presence ≥1 patient risk factor ( &gt; 65 yr , extensive bone marrow involvement prior extensive radiotherapy bone tissue Prior chemotherapy ECOG performance status 2 , grade 2 high liver function abnormality ) . That , patient start docetaxel second part FECD eligible last 3 docetaxel cycle , increase risk febrile neutropenia , e.g . elderly age . Able comply protocol . Written inform consent obtain prior study specific screen . Active uncontrolled infection . Inadequate renal hepatic function . Any evidence history hypersensitivity contraindication GCSF medication . Not recover acute toxicity prior therapy . Absolute neutrophil count ( ANC ) &lt; 1.5 x 109/l , cause bone marrow involvement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Advanced</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Prevention</keyword>
	<keyword>Febrile neutropenia</keyword>
</DOC>